semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Patients with invasive breast cancer (T1-T3) N0 on palpation Preoperative ultrasound performed Pathology report shows macrometastasis in 1-2 sentinel lymph nodes Patients undergo breast-conserving therapy or mastectomy The patient must have provided oral and written consent Age ≥ 18 years  Metastases outside of the ipsilateral axilla Prior history of invasive breast cancer Pregnancy Bilateral breast cancer if one side meets Medical contraindication for radiotherapy or systemic treatment Inability to absorb or understand the meaning of the study information; for example, through disability, inadequate language skills or dementia
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Known or suspected breast cancer  Inability to sign informed consent Known bleeding disorder Use of anticoagulant medications (heparin, warfarin, etc.) within one week prior to biopsy Use of antiplatelet medications (aspirin, clopidogrel, etc.) within one week prior to biopsy
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 30.0-49.0,  Cervical Neoplasia Cervical Cancer female, age 30-49, able to give informed consent  pregnancy, gross cervical mass, prior cervical cancer, unable to give informed consent, prior complete hysterectomy, allergic to acetic acid
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Female participants Postmenopausal status Histologically confirmed invasive breast carcinoma, with all of the following characteristics: (i) Primary tumor greater than or equal to (>/=) 2 centimeters (cm) in largest diameter (cT1-3) by MRI; (ii) Stage I to operable Stage III breast cancer; (iii) Documented absence of distant metastases (M0) Estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer Breast cancer eligible for primary surgery Tumor tissue from formalin-fixed paraffin-embedded cores (FFPE) core biopsy of breast primary tumor that is confirmed as evaluable for phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) mutation status by central histopathology laboratory Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Fasting glucose less than or equal to (</=) 125 milligrams per deciliter (mg/dL) Adequate hematological, renal, and hepatic function Absence of any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule  Any prior treatment for primary invasive breast cancer Participants with cT4 or cN3 stage breast tumors Bilateral invasive, multicentric, or metastatic breast cancer Participants who have undergone excisional biopsy of primary tumor and/or axillary lymph nodes or sentinel lymph node biopsy Type 1 or 2 diabetes requiring antihyperglycemic medication Inability or unwillingness to swallow pills Malabsorption syndrome or other condition that would interfere with enteric absorption History of prior or currently active small or large intestine inflammation (such as Crohn's disease or ulcerative colitis). Any predisposition for gastrointestinal (GI) toxicity requires prior approval from the Medical Monitor Congenital long QT syndrome or QT interval corrected using Fridericia's formula (QTcF) >470 milliseconds (msec) Diffusing capacity of the lungs for carbon monoxide (DLCO) <60% of the predicted values
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-70.0,  Breast Cancer Histologically documented invasive adenocarcinoma (any subtype) of the breast with clinical stage T1-2 (0-5 cm) and pathologic stage N0-1, M0 disease Lumpectomy with 1-2 cm margin required within 9 weeks of initiation of protocol radiotherapy Axillary dissection required for premenopausal patients and recommended for postmenopausal patients (Irradiation of clinically negative axilla is an acceptable alternative to axillary dissection in postmenopausal patients)  Residual microcalcification on postoperative mammogram Gross residual disease in the breast (re-excision allowed if there is gross residual disease after first surgical procedure) Multiple foci of tumor in more than 1 quadrant Previous or concurrent malignant tumor in contralateral breast In situ carcinoma of the breast, without invasive tumor Tumorectomy performed more than 9 weeks before the start of radiotherapy in cases where no adjuvant chemotherapy is given and more than 6 months before the start of radiotherapy if chemotherapy is given Previous history of malignant disease, except adequately treated carcinoma in situ of the cervix or basal cell carcinoma of the skin Concurrent pregnancy or lactation Eastern Cooperative Oncology Group performance scale more than 2
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-99.0,  Advanced/Metastatic Breast Cancer Breast Cancer (Early Breast Cancer) for the early breast cancer setting Adult breast cancer patients (age ≥18 years) Patients with breast cancer and no evidence of distant metastases with a diagnosis not longer than 91 days before study entry Patients, who are able and willing to sign the informed consent form for the advanced/metastatic setting Adult women aged ≥18 years Patients with the diagnosis of invasive breast cancer (in German: Mammakarzinom, as op-posed to "non-invasive"= ductales Carcinoma in situ; irrespective of status of BC, e.g. TNM, re-ceptor status etc.) and Patients, who are willing and able to sign the informed consent form Patients with metastatic or locally advanced, inoperable disease proven by clinical measures (i.e. standard imaging)  Patients who did not sign the informed consent form Patients, who are not eligible for observation due to non-availability and/or severe comor-bidities as evaluated by the treating physician
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hormone Receptor Positive Malignant Neoplasm of Breast Patients must have undergone surgical treatment for breast cancer with adequate evaluation of lymph node status with a sentinel lymph node procedure or full axillary dissection, with positive involvement of 1-3 axillary lymph nodes as confirmed by histologic examination ECOG performance status 0 or 1 Patient must be a candidate for treatment of their cancer with systemic chemotherapy in addition to hormonal therapy Eligible Staging T1-3 N1 M0 Breast tumor must undergo central pathology review at GHI and must be found adequate for the Oncotype DX assay Breast tumor must be estrogen-receptor positive and HER2 positive (IHC/FISH) as per institutional guidelines  Patient has a prior history of breast cancer in the same breast Patient as been newly diagnosed with more than one operable primary breast tumor Patient has multi-centric tumors (note: patients with multi-focal tumors may be included) Patient has known metastatic breast cancer Patient has <2mm invasive tumor as assessed by local pathologist Patient has received any kind of neoadjuvant treatment Presence of clinical factors rendering the patient a non-viable candidate for adjuvant chemotherapy Presence of a current medical condition that would interfere with patient's ability to consent and participate in this study
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-95.0,  Node Positive Breast Cancer Women with node positive breast cancer treated with surgery, anthracycline-based or similar cardiotoxic chemotherapy, and regional nodal irradiation between 2000-2007  Women who have not received anthracycline-based or similar cardiotoxic chemotherapy, and regional nodal irradiation between 2000-2007
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Metastatic Breast Cancer Aged ≥18 and ≤70 years ECOG performance status of 0 to 1 Life expectancy of more than 12 weeks At least one measurable lesion exists.(RECIST 1.1) Histologically or cytologic confirmed HER2 positive metastatic breast cancer which failed prior therapies No previous treatment of capecitabin during the past 1 year Required laboratory values including following parameters: ANC: ≥ 1.5 x 109/L Platelet count: ≥ 100 x 109/L Hemoglobin: ≥ 9.0 g/dL Total bilirubin: ≤ 1.5 x upper limit of normal, ULN ALT and AST: ≤ 1.5 x ULN BUN and creatine clearance rate: ≥ 50 mL/min LVEF: ≥ 50% QTcF: < 470 ms Signed informed consent  Subjects with third space fluid that can not be controled by drainage or other methods Steroid treatment for more than 50 days, or in need of long-term use of steroids Subjects that are unable to swallow tablets, or dysfunction of gastrointestinal absorption Less than 4 weeks from the last radiotherapy,chemotherapy，surgery，hermone treatment,target therapy, or less than 6 weeks from the nitrosoureas or mitomycin chemotherapy Subjects with no efficacy during the previous treatment of capecitabine Subjects with uncontrolled hypokalemia and hypomagnesemia before study entry Subjects who can not interrupt the using of the drugs that may cause QT prolongation during study Subjects with intracranial lesions Subjects with bone or skin as the only target lesion Treated or treating with HER2 tyrosine kinase inhibitors (TKIs) before study entry
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 45.0-999.0,  Early Stage Breast Cancer Neoplasm of the Breast Breast Tumor Female Age 45 or greater Diagnosed with operable invasive breast cancer, T1 and T2 (< 3.5 cm), N0, M0, confirmed by cytological or histological examination Suited for breast conserving surgery Have had an ipsilateral (same side as current cancer) diagnostic mammogram within 12 months of enrollment  age 44 or less Axillary lymph node positive breast cancer Invasive lobular cancer Tumor size > 3.5 cm Extensive Intraductal Component (EIC= > 25% of the lumpectomy specimen involved with ductal carcinoma in situ, DCIS) as assessed on surgical pathologic lumpectomy specimen Multicentric cancer in the same breast not amenable to excision with a single lumpectomy Inability to assess pathologic margin status Synchronous bilateral breast cancer at the time of diagnosis Ipsilateral breast had a previous cancer and/or prior in-field radiation Patients known to have BRCA1/2 gene mutations
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 50.0-99.0,  Breast Cancer DCIS Invasive Ductal Carcinoma -Newly diagnosed Stage 0 or I breast cancer On histological examination, the tumor must be DCIS or invasive non-lobular carcinoma of the breast Surgical treatment of the breast must have been wide excision, lumpectomy or partial mastectomy Age 50 years or greater ER positive: (≥1% of breast tumor cells express ER in their nuclei) PR (progesterone receptor) positive: (≥ 1% of breast tumor cells express PR in their nuclei) Her2 negative (IHC 0-1+; for IHC 2+, FISH (fluorescence in situ hybridization) must be non-amplified) Subjects with invasive tumors should undergo axillary sentinel lymph node evaluation or axillary lymph node dissection Negative inked surgical margins of excision or re-excision, clear of invasive tumor (no cells on ink) and DCIS by at least 1 mm Negative post-excision or post-reexcision mammography if cancer presented with malignancy-associated microcalcifications with no remaining suspicious calcifications in the breast before radiotherapy. Alternatively, a specimen radiograph can be obtained showing all the suspicious calcifications  -Patients with invasive lobular carcinoma or nonepithelial breast malignancies such as sarcoma or lymphoma Patients with tumors greater than 2 cm Patients with surgical margins which cannot be microscopically assessed or not cleared by at least 2mm at pathological evaluation Patients with multicentric carcinoma or with other clinically or radiographically suspicious areas in the ipsilateral breast unless confirmed to be negative for malignancy by biopsy. Breast MRI will be recommended to multicentric disease and additional suspicious areas will require biopsy to malignancy Patient with lymphovascular space invasion (LVSI) Patients with involved axillary nodes Patients with collagen vascular diseases Patient with known deleterious BRCA1/2 mutations or known mutations in other high penetrance genes (TP53, STK11, PTEN-phosphatase and tensin homolog, CDH1) Patients with prior ipsilateral breast irradiation Patients with prior ipsilateral thoracic irradiation
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Orthopedic Procedures, Tranexamic Acid Osteoarthrosis TKR operation elective ASA I-III  TKR due to any reason but osteoarthrosis known coagulation problems platelets < 100,000/DcL Hb < 12 g% past thrombo-embolic event treatment with aspiring during last week treatment with NSAID's during last 48 hours malignancy known allergy to tranexamic acid general anesthesia
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  HER2-positive Breast Cancer Patients ≥ 18 years of age with histologically, and radiographically confirmed non-metastatic breast cancer with minimal tumor size over 1 cm (≥T1c lesion) to receive neoadjuvant chemotherapy recommended by the treating physician For estrogen receptor (ER) strongly positive, human epithelial receptor (HER2) negative breast cancer, Oncotype Dx study is required. Patients with low recurrence score will be excluded in the study Eastern Cooperative Oncology Group (ECOG) performance status score < 1 Absolute neutrophil count > 1500 mm3, platelet count ≥ 100×109 L, hemoglobin ≥ 8.5 g/dL Serum creatinine ≤1.5 times the upper limit of the normal range, total bilirubin ≤ 1.5 X ULN (≤ 3 mg/dL if clinically diagnosed with Gilbert syndrome) AST/ALT ≤ 2.5 X ULN (AST/ALT ≤ 5X ULN if clinically diagnosed with Gilbert syndrome) Willing to provide blood samples for correlative research purposes Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must be willing to use an acceptable contraceptive method (abstinence, oral contraceptive or double barrier method) for the duration of the study and for 30 days following the last dose of study drug, and must have a negative urine or serum pregnancy test within 2 weeks prior to beginning treatment on this trial  Uncontrolled cardiac disease, such as angina, hypertension or significant arrhythmias, congestive heart failure (NYHA grade 2 or more or LVEF < 40% on any prior assessment). Note: Assessment of LVEF is done before and after anthracycline-based or trastuzumab-based chemotherapy as standard of care 2. Pregnant or lactating females 3. Known history of diabetes mellitus. If screening fasting glucose is ≥126 mg/dL, an HbA1C must be < 6.5%. 4. History of syncope with calorie restriction in the past 5. Body mass index (BMI) < 19 kg/m2 6. Clinical signs or symptoms of GI obstruction and/or requirement for parenteral hydration or nutrition 7. Inability to complete informed consent process and adhere to the protocol treatment plan and follow-up requirements 8. Concurrent severe illness such as active infection, or psychiatric illness/social situations that would limit safety and compliance with study requirements 9. Any other medical comorbidity that requires daily medication(s) that may not be safely taken without food
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Newly diagnosed infiltrating ductal carcinoma (IDC) of the breast >= 1.0 cm primary tumor Calculated creatinine clearance >= 50 mL/min Willing and able to provide informed consent Age ≥ 18 years ECOG performance status 0-2 Informed of the investigational nature of this study  Allergy to iodinated contrast agent Use of metformin, aminoglycosides, other nephrotoxic medications, or daily use of NSAIDs Diabetes mellitus History of severe claustrophobia Presence of electrically, magnetically, or mechanically activated implants including cardiac pacemakers, cochlear implants, magnetic surgical clips or prosthesis that would preclude MRI Use of > 1 antihypertensive drug Pregnancy or breastfeeding Paraproteinemia syndromes or multiple myeloma Collagen vascular disease Active hyperthyroidism